Objective: Bone morphogenetic protein 2 (BMP-2, encoded by BMP2) and Indian hedgehog protein (IHH, encoded by IHH) are well known regulators of chondrogenesis and chondrogenic hypertrophy. Despite being a potent chondrogenic factor BMP-2 was observed to induce chondrocyte hypertrophy in osteoarthritis (OA), growth plate cartilage and adult mesenchymal stem cells (MSCs). IHH might induce chondrogenic differentiation through different intracellular signalling pathways without inducing subsequent chondrocyte hypertrophy. The primary objective of this study is to test the efficacy of direct BMP2 and IHH gene delivery via bone marrow coagulates to influence histological repair cartilage quality in vivo. Method: Vector-laden autologous bone marrow coagulates with 10 11 adenoviral vector particles encoding BMP2, IHH or the Green fluorescent protein (GFP) were delivered to 3.2 mm osteochondral defects in the trochlea of rabbit knees. After 13 weeks the histological repair cartilage quality was assessed using the ICRS II scoring system and the type II collagen positive area.
Introduction
Available cell based treatments for articular cartilage repair fail to persistently restore hyaline articular cartilage in vivo 1 . One of the reasons for this failure, is an insufficient chondrogenic differentiation of transplanted or local multipotent cells 2 . To overcome this limitation, the delivery of relevant factors has been proposed as treatment option 2 . Several growth factors have been shown to stimulate chondrogenesis, including members of the transforming growth factor (TGF)-b superfamily 2, 3 . One member of this family, bone morphogenetic protein 2 (BMP-2, encoded by BMP2), is emerging as a potent inducer of chondrogenesis in vitro 4e6 and in vivo
7e9
. BMP-2 is affecting gene expression via members of the SMAD protein family or mitogen-activated protein (MAP) kinase pathways after binding to BMP type I and type II receptors at the cell membrane 10, 11 . However, along with other factors, it was observed to induce chondrocyte hypertrophy in osteoarthritis (OA), growth plate cartilage and adult mesenchymal stem cells (MSCs) in vitro 2, 6, 12 . While the induction of intralesional hypertrophy and bone formation in cartilage defects by BMP-2 was discussed previously, there is only limited data on this topic to date 2 . To achieve persistent hyaline cartilage regeneration, the stimulation of chondrogenic differentiation using different, nonhypertrophic, pathways is desirable 2 . The growth plate regulating Indian hedgehog protein (IHH, encoded by IHH) is an attractive candidate growth factor, which is observed to effectively induce chondrogenesis of MSCs in vitro, without driving chondrocyte hypertrophy 13, 14 . IHH is affecting gene expression via Gli transcription factors 14 . Although BMP signalling might affect the IHH gene expression, no extensive activation of BMP signalling by IHH is described to date 15 . Despite of promising results in vitro, it is not known if IHH is capable of inducing chondrogenesis in cartilage defects in vivo.
The objective of this proof of concept study was to determine if IHH is capable to improve cartilage repair quality in vivo and thus resembles an attractive alternative growth factor candidate. Specifically, we hypothesized, that direct adenoviral gene transfer of IHH or BMP2 into osteochondral defects, using autologous vectorladen bone marrow coagulates, results in higher histological repair cartilage quality and higher type II collagen deposition, than the transfer of GFP (encoding for the non-chondrogenic green fluorescent protein). Bone marrow coagulates in combination with adenoviral vectors were previously shown to be an efficient direct gene delivery system for the treatment of osteochondral defects 16, 17 .
Methods

Experimental animals, allocation, outcomes and comparisons
This controlled small-animal experiment was performed as approved by the Institutional Review Board of the JuliusMaximilians-University of Würzburg, Germany. Reporting is guided by the ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines 18 . Ten female, skeletally mature New Zealand White Rabbits (with a mean weight of 3.11 kg ± 0.22 kg standard deviation; Charles River, Kißlegg, Germany) were randomly assigned to the respective groups: n ¼ 4 animals in the IHH and n ¼ 3 in the BMP2 treatment groups, as well as n ¼ 3 in the GFP control group. All animals received one osteochondral defect in each of their knees. In a one-stage procedure the defects were filled with an autologous bone marrow coagulate in combination with adenoviruses carrying complementary DNA (cDNA) of the respective transgene [ Fig. 1(a)e(d) ]. According to the allocation of the animal, the same gene was transferred in both knees, thus each animal contributed two observations. One additional animal was used to characterize the morphology of the treated lesion at the day of surgery [ Fig. 1(e) ].
Histological scoring, using the overall assessment parameter of the semiquantitative International Cartilage Repair Society II histological scoring system (ICRS II) 19 and type II collagen deposition (assessed by immunohistomorphometry) were designated as primary outcomes. Further, we assessed the remaining ICRS II parameters, the type X collagen deposition (as a marker of chondrocyte hypertrophy) and the type I collagen deposition (as a marker of fibrocartilage). The BMP2 and IHH treated animals where compared to GFP controls at 13 weeks after surgery, which has previously been reported to be an appropriate time to evaluate long-term repair results in rabbits 20 .
Adenoviral vectors
The first-generation, early region 1 and 3 (E1 and E3) deleted, serotype five adenoviral vectors carrying BMP2, IHH or GFP cDNA were previously generated and amplified as described before 6, 21 . Suspensions of recombinant adenovirus were prepared by amplification in human embryonic kidney 293 cells followed by purification using three consecutive caesium chloride gradients 21 . Viral titres were estimated to be between 10 12 and 10 13 particles/ml by optical density at 260 nm and standard plaque assay 21 .
Intervention, gene transfer system and animal care
Autologous bone marrow coagulates containing adenoviral vectors, were used as gene transfer system, as described and characterized before 16 . Briefly, animals received 10 mg xylazine (Bayer Vital, Leverkusen, Germany) and 200 mg ketamine adenoviral vector particles carrying the respective gene (either IHH, BMP2 or GFP) into each well (a). Exposure of the femoral trochlea using a medial arthrotomy and generation of a 3.2 mm diameter osteochondral defect (b). The vector-laden bone marrow coagulate was obtained from the 96-well plate using forceps and implanted into the lesion without additional fixatives (c, d). Capsule, subcutaneous tissue and skin were closed in layers and the procedure was repeated for the contralateral knee (not shown). Type II collagen staining of the osteochondral defect after press-fit implantation of the autologous vector-laden bone marrow coagulate. Native adjacent cartilage and subchondral bone is depicted on the right side of the picture, while the vector-laden bone marrow coagulate is depicted on the left side. Note, that fixation and demineralization was necessary, which may have altered the coagulate surface. Bar representing 500 mm (e).
(Medistar, Ascheberg, Germany) intra muscular (i.m.) to induce and isoflurane (Abbott, Wiesbaden, Germany) to maintain anaesthesia. One ml of metamizol (Ratiopharm, Ulm, Germany) i.m. was administered perioperatively and 5 gtt of tramadol (Ratiopharm) per 500 ml of drinking water was given for the first 5 days after surgery. Infection prophylaxis was performed using an i.m. injection of procaine-benzylpenicillin (60.000 IU/kg; Pfizer, Karlsruhe, Germany) perioperatively. Bone marrow was aspirated from the iliac crest under aseptic conditions [ Fig. 1(a) ]. 200 ml aliquots were each mixed with 1 Â 10 11 adenoviral vector particles carrying the respective gene in a generic 96-well culture plate. Aliquots were allowed to form coagulates for 5 min at room temperature. Under sterile conditions, femoral trochleae were exposed by mediopatellar arthrotomies. Central osteochondral defects were created perpendicular to the surface using a 3.2 mm diameter drill bit aiming for a depth of 5 mm [ Fig. 1(b) ]. The vector-laden bone marrow coagulates were then press-fitted into the lesions. No additional fixative was necessary [ Fig. 1(d) ]. Capsule, subcutaneous tissue and skin were sutured separately. All animals were allowed to move freely in their cage at all times after surgery. A 12 h nightday cycle was simulated in the animal care facility. After 13 weeks, animals received a 10 mg xylazine and 200 mg ketamine i.m. to induce deep anaesthesia before administration of 15 mg tetracain-hydrochloride, 150 mg mebezonium-iodide and 600 mg embutramide (T61, Intervet, Unterschleißheim, Germany) into the ear-vein for euthanasia. Femoral diaphyses were cut proximally of the trochlea to obtain the distal femurs. After complete removal of the joint capsule, the epicondyles were removed using a chisel.
Processing of histological specimens
The distal femurs were fixed in neutralized 4% paraformaldehyde for 11 weeks, demineralized in Calci-Clear Rapid (National Diagnostics, Atlanta, Georgia, USA) and embedded in Paraffin. Embedded specimens were stored at À20 C. Four representative 4 mm slides from the center of the defects (defined by a diameter >80% of the drill bit diameter, corresponding to >2.6 mm) were obtained. For each knee, one haematoxylin eosin (HE), one type II collagen (as a marker of hyaline cartilage 20 ) one type I collagen (as a marker of fibrocartilage
20
) and one type X collagen staining (as a marker of chondrocyte hypertrophy 6 ) was prepared (Table I) . Negative controls with equally concentrated mouse serum replacing the antibodies were carried out along with each batch. For antibody detection, a streptavidin-biotin interaction based kit using alkaline phosphatase to catalyse fast red was used (SuperSensitive TM Link-label IHC Detection System, BioGenex, Fremont CA, USA). Endogenous alkaline phosphatase was blocked by addition of levamisole hydrochloride (Sigma, St. Louis MO, USA).
Photomicrographs were obtained in a square scanning pattern, using a Carl Zeiss Axioskop microscope with a 10Â objective, an AxioCam ICc 1 camera and the Axiovision 40 software Version 4.7.2.0 (Carl Zeiss MicroImaging, Jena, Germany). Images were merged using the photomerge tool of Adobe Photoshop CS5 Extended Version 12.0.4 (Adobe Systems, San Jose CA, USA) without allowing for scaling or rotational changes. Each composed photomicrograph was revised manually to ensure correct alignment, if necessary. The final images that were used for the histological scoring provided an overview over the whole cartilage surface and the former lesion, with the possibility to zoom in on important details.
ICRS II histological scoring and histomorphometry
ICRS II scoring was performed by three independent and blinded readers (AS, FG, MK). Briefly, this semiquantitative scoring system evaluates 14 parameters regarding chondrocyte phenotype, biochemical matrix properties and tissue structure. Scoring is performed using a visual analogue scale ranging from 0 to 100, with 100 indicating ideal cartilage features 19, 20 . Scores were averaged between readers and interreader correlations were calculated. Scoring of the parameter matrix staining could not be performed, because glycosaminoglycan detection was not possible in repair and native cartilage using alcian blue, fast-green/safranin O or immunhistochemical staining for chondroitin sulphate-4 and aggrecan, most probably due to the long fixation period 22 .
Histomorphometry was performed using Adobe Photoshop CS5 Extended Version 12.0.4 (Adobe Systems). The pre-interventional cartilage area was defined as region of interest and named chondral defect area, which was measured by drawing B ezier-curves (unpublished protocol available on request) as projections of subchondral bone interface and cartilage surface with lateral boundaries perpendicular to the joint surface. Within the defined chondral defect area, the area of positive type II collagen staining was manually labelled without blinding (JS). Histomorphometric results are displayed as type II collagen positive area (%) and were calculated as (area of type II collagen positive staining/chondral defect area) Â 100.
Statistical methods
To gauge the reliability of the scoring method, the correlation between observers was determined for each assessed parameter, using SPSS Statistics Version 19 (IBM, Armonk NY, USA). Pearson's r > 0.6 was considered as high correlation between readers, r > 0.5 as moderate correlation and r < 0.5 as low correlation (Table II) .
Group means and corresponding 95% confidence intervals (95% CI) were estimated using a linear mixed model. This model accounts for a possible correlation of the observations that were made in the left and right knee within one animal (proc mixed function of SAS, SAS Institute, Cary, NC, USA) ( Table III) . The linear mixed model was also used to obtain point estimates describing the difference between the groups and corresponding P values (lme function of the NMLE package 23 in R version 3.1.0.; P values are included in Table III ). Differences were considered as statistically significant, when P < 0.05. 
Results
Qualitative assessment of neo-cartilage tissues
At 13 weeks after surgery most of the BMP2 (four of six observations) and all of the IHH (eight of eight observations) treated joints showed hyaline-like cartilage repair, while the GFP control joints (six of six) showed repair tissue of inferior quality in the histological assessment. In two BMP2 treated joints severe intralesional bone formation (Fig. 2) was observed, whereas no intralesional bone formation was observed in any IHH treated joints or GFP controls. The joints with severe intralesional bone formation exhibited most of the following characteristics: Osseous repair tissue over the preinterventional cartilage surface, absence of a cartilage cover, few or absent type II collagen positive repair tissue and presence of strong type X collagen deposition in the repair tissue (Fig. 2) .
Correlation between observers
A high correlation between the three observers was found regarding the ICRS II parameter overall assessment (primary outcome) and the secondary outcomes cell morphology, surface architecture, formation of a tidemark, subchondral bone abnormalities, abnormal calcifications, surface/superficial assessment and mid/ deep zone assessment (Table II) . Scores correlated moderately between observers for the parameters tissue morphology, basal integration and vascularization. Low correlations are only observed for chondrocyte clustering and inflammation, precluding conclusions regarding these features of cartilage repair tissue in this report.
Primary outcomes: ICRS II overall assessment and type II collagen positive area (%)
The increased deposition was not considered as statistically significant (P ¼ 0.093). The observed means and 95% CI of all groups, as well as the P values for the comparison of each treatment group with the control group is available in Table III and plotted in Fig. 3 .
Secondary outcomes: ICRS II parameters at 13 weeks after surgery
In the comparison of BMP2 with the control group, no significant differences were observed in any ICRS II parameter. In contrast, IHH resulted in higher scores than controls in all of the assessed parameters, reaching the level of statistical significance in five out of the remaining 12 assessed parameters. Namely, a 21.5 (3.6, 39.4) points increased score for the parameter tissue morphology was observed, as well as þ21.0 (6.4, 35.7) for chondrocyte clustering, þ31.2 (0.8, 61.5) for formation of a tidemark, þ17.3 (0.2, Table III The repair results of IHH or BMP2 treatment and the GFP control at 13 weeks after surgery are displayed as group means and 95% CI (lower limit, upper limit) of each assessed ICRS II parameter, as well as the type II collagen positive area (percentage of the initial chondral defect area, as assessed by histomorphometry). A score of 100 indicates hyaline cartilage features or type II collagen deposition throughout the whole area of the former chondral defect. A linear mixed model was used to determine the significance level of the observed group differences between IHH treatment (eight observations (obs.)) and GFP controls (six obs.), as well as between BMP2 treatment (six obs.) and GFP controls. The utilized model is accounting for possible correlations of the bilateral observations obtained from the independent animals (n shown in respective columns) Fig. 3 ).
Detection of chondrocyte hypertrophy markers
Using immunohistochemistry, we observed a pericellular pattern of type X collagen deposition in all groups [ Fig. 4(p)e(t) , Fig. 5(p)e(t) ]. Markedly higher type X collagen deposition was only observed in joints with severe intralesional bone formation after BMP2 treatment [ Fig. 2 (j)e(l) ].
Discussion
This experiment is the first to assess the efficacy of IHH to induce hyaline cartilage repair of osteochondral lesions in vivo. Specifically, we have confirmed our hypothesis that direct adenoviral gene transfer of IHH into osteochondral defects, using autologous vectorladen bone marrow coagulates, results in higher histological repair cartilage quality (as assessed with the ICRS II histological scoring system 19 ) and higher type II collagen deposition, than the transfer of non-chondrogenic GFP, while we reject our hypothesis regarding Fig. 2 . Intralesional bone formation after BMP2 gene transfer. HE staining (aec), type II collagen immunohistochemical staining (def), type I collagen (gei), type X collagen (jel) and negative control of type X collagen staining (meo) depicting the intralesional bone formation observed 13 weeks after BMP2 treatment. The depicted joint is demonstrating bone formation over the level of the pre-interventional surface (e), absence of type II collagen in the defect area (e), strong type X collagen deposition in the few remaining cartilage isles (as highlighted by the arrow in l). Note the strong type X collagen deposition in the adjacent cartilage (arrow in j), where concomitant chondrocyte hypertrophy can be observed (arrow in a). Bar representing 1 mm in panorama views (b, e, h, k, n) and 500 mm in close-up views (a, c, d, f, g, i, j, l, m, o) .
the beneficial effects of BMP2 gene transfer. We have demonstrated that IHH gene transfer results in increased scores throughout all of the assessed parameters, when compared to controls, while BMP2 did not. Though higher scores have been consistently observed after IHH transfer throughout all parameters, the conventional levels of statistical significance were not achieved for the designated primary outcomes (P ¼ 0.052 and P ¼ 0.093 for the ICRS II overall assessment parameter and the type II collagen Fig. 3 . Histological repair cartilage quality at 13 weeks after the treatment with BMP2, IHH or the transfer of non-chondrogenic GFP. Dot-plots depicting the results in 12 of the 14 assessed parameters (chondrocyte clustering and inflammation is not shown, due to the low correlation between the three observers in those parameters). Depicted are bilateral observations made from the left and the right knee joint of n ¼ 3, 4 and 3 independent animals for GFP, IHH and BMP2, respectively. Each dot represents one joint; both joints of each animal were allocated to the same treatment group. Horizontal bars represent the group means, vertical bars the 95% CI. The intervals were estimated using a linear mixed model accounting for possible correlations between both knees of each animal. While the observed difference in the primary outcomes (Type II collagen positive area (%) and the ICRS II parameter 14. overall assessment) was not considered as statistically significant, IHH was significantly superior to GFP in the ICRS II parameters 1. Tissue morphology, 7. Tidemark formation, 10. Abnormal calcification and 13. Mid/deep zone assessment. BMP2 treated joints were not significantly different from the GFP controls. histomorphometry, respectively), thus the appropriate caution needs to be warranted when generalizing the here observed effects on those parameters. However, several effects on the parameters designated as secondary outcomes were considered to be statistically significant (P < 0.05). In summary, we have observed an improved tissue morphology (assessed by polarized light microscopy), tidemark formation, mid and deep zone morphology, as well as reduced abnormal calcifications after IHH gene transfer. In spite of the exploratory character of this experiment we did not correct for the testing of multiple hypotheses. We further assessed the efficacy of BMP2 gene transfer, which has been previously described to increase repair cartilage quality in vivo (using recombinant Escherichia coli-derived protein or other gene transfer systems) 7e9 . We observed a high variance in the results after BMP2 gene transfer, ranging from hyaline-like cartilage to severe intralesional bone formation. In spite of the substantial overlap with the results of the control group, we were not able to replicate the beneficial effect of BMP2 on cartilage repair quality that has been observed by other authors 7e9 .
The primary objective of this study was to prove the concept that IHH can be used as an alternative to BMP2 or other TGF-b superfamily members. Such alternatives might ultimately allow to induce chondrogenesis through signaling pathways that do not induce chondrocyte hypertrophy and subsequent deterioration of the repair results. This study was limited to the histological assessment of the tissue morphology (supplemented with polarized light microscopy to describe the organization of the collagen fibres) and the collagen composition using immunohistochemistry to detect type I, type II and type X collagen. An assessment of the matrix glycosaminoglycan content could unfortunately not be performed despite comprehensive efforts, due to an extensive fixation and demineralization of the samples (see Hoemann et al. for detailed recommendations on histoprocessing of various osteochondral samples 20 ). Though collagen composition and organization are important for the mechanical properties of repair cartilage tissue they are not established surrogate markers for the actual mechanical properties, which to date can only be evaluated by biomechanical testing (such as indentation). Further, the sole histological assessment is limited to the reviewed slides and do not necessarily depict the tissue quality throughout the defect. Though valuable, we did not perform biomechanical testing in order to ensure the sample integrity for the histological analysis. Likewise, biochemical and molecular-biological assays are highly valuable to determine the cell types involved in the repair process, to determine the duration of transgene expression, as well as the effects of the delivered gene on the expression of target genes (such as those encoding for collagens and proteoglycans). However, those assays would again compromise the histological assessment and the Fig. 4 . Histological analyses of the BMP2 treatment and GFP control group at 13 weeks. HE staining (aee), type II collagen immunohistochemical staining (fej), type I collagen (keo) and type X collagen (pet) of the BMP2 treatment and GFP control group 13 weeks after surgery. The HE stain depicts fibrocartilaginous repair tissue in the GFP control group (b, c), which is confirmed by the presence of type I collagen (l, m) and reduced type II collagen (g, h) throughout large parts of the tissue. In contrast the BMP2 treated joint is demonstrating hyaline-like features in the HE staining (d, e), presence of type II collagen throughout the whole repair cartilage (i, j) and few concomitant type I cartilage deposition (highlighted by the arrow in o). In general type X collagen deposition as a marker for chondrocyte hypertrophy is observed in a pericellular manner (indicated by arrows in p, r, t). The deposition appears to be slightly increased in the BMP2 treatment groups in the shown specimens, but no substantial differences are observed between the native cartilage and the repair cartilage of GFP controls and BMP2 treated joints (pet). Bar representing 1.5 mm in panorama views (b, d, g, i, l, n, q, s) and 500 mm in close-up views (a,c, e, f, h, j, k, m, o, p, r, t).
number of research animals necessary for such studies would hardly be justifiable without a proof of IHH's in vivo efficacy. Now, after this proof of concept, detailed in vivo studies to replicate our findings and to address the underlying mechanisms of IHH induced cartilage repair are justified.
Vector-laden bone marrow coagulates for direct gene transfer into cartilage defects
The utilized gene transfer system was previously shown to be effective for direct gene transfer into osteochondral defects, using marker genes encoding for firefly luciferase, beta-galactosidase and GFP 16 . Though being effective without the addition of cells, this system does not allow to adjust the cell count. The number of nucleated cells tends to vary greatly between different bone marrow aspirations from the same animal, but not between coagulates aliquoted from the same aspiration 16 . Therefore, only coagulates from the initial aspirates were used for our experiments. Pascher et al. described, that the differences in in vitro transgene expression reflect the number of nucleated cells available for genetic modification in each sample 16 . The observed intralesional bone formation might just resemble the response to a high BMP2 transgene expression in the respective knee joints. Unfortunately, in vivo transgene expression, nor SMAD or MAP kinase activation could be assessed within this experiment in order to maintain the integrity of the tissue for the histological analysis. After vectorladen bone marrow coagulates have been characterized by Pascher et al. using marker genes 16 , Ivkovic et al. demonstrated the feasibility of this system to deliver chondrogenic genes into chondral defects in a sheep model, utilizing adenoviral vectors to deliver TGFB1 cDNA (encoding TGF b-1) 17 . TGFB1 gene transfer was shown to result in a substantially higher type II collagen deposition than GFP controls. However, an extensive type I collagen deposition indicated fibrocartilaginous repair 17 . In summary, vector-laden bone marrow coagulates resemble an effective system for preclinical evaluation of chondrogenic agents, although TGFB1 vectorladen bone marrow coagulates were not capable to fully restore histological cartilage quality in an ovine large animal model 17 .
BMP-2 and IHH for articular cartilage repair
Though the proof of IHH's efficacy was the primary objective of this experiment, the attractiveness of IHH for further development towards clinical application is based on the potentially reduced rate Fig. 5 . Histological analyses of the IHH treatment and GFP control group at 13 weeks. HE staining (aee), type II collagen immunohistochemical staining (fej), type I collagen (keo) and type X collagen (pet) of the IHH treatment and GFP control group 13 weeks after surgery. The HE stain shows fibrocartilaginous repair tissue in the right half of the defect that has received GFP gene transfer (b, c), which is confirmed by the presence of type I collagen in the respective area (highlighted by the arrow in l) and a concomitantly reduced type II collagen deposition (arrow in g). In contrast the IHH treated joint is demonstrating hyaline-like features in the HE staining (d, e), presence of type II collagen throughout the whole repair cartilage (i, j) and absence of type I cartilage deposition (n, o). The depicted specimen of the IHH treatment group is demonstrating an impaired reconstitution of the subchondral bone (arrows in n), which was not a consistent finding in the other IHH specimens, nor reflected in the scores of the ICRS II parameter subchondral bone abnormalities/ marrow fibrosis. Regarding the deposition of the chondrocyte hypertrophy marker type X collagen, no substantial differences are observed between the repair cartilage of GFP controls and IHH treated joints (r, t). Type X collagen was generally deposited in a pericellular manner (arrows in r, t). Bar representing 1.5 mm in panorama views (b, d, g, i, l, n, q, s) and 500 mm in close-up views (a, c, e, f, h, j, k, m, o, p, r, t).
for adverse events which was observed for members of the TGF-b superfamily, including fibrosis of the synovial membrane, chondrocyte hypertrophy and consecutive osteophyte formation 24e26 .
Specifically, the direct gene transfer of TGFB1 to synovial lining cells by intraarticular injection of adenoviral vectors resulted in fibrosis and ectopic chondrogenesis in native and arthritic leporine knee joints 24 , as well as in native knee joints of immunocompromised rats 25 . Using a method of indirect in vivo gene therapy, Gelse et al.
transplanted perichondrial mesenchymal stromal cells after ex vivo transduction with adenoviral vectors carrying BMP2 genes into chondral defects of rat knees 26 . Even though an indirect method of gene transfer was used, dislocated cells expressing BMP2 induced osteophyte formation in 15 of the 16 treated joints 26 . Using a protein based delivery of recombinant human BMP-2 in combination with a collagen matrix into leporine chondral defects resulted in no substantial difference in the rate of osteophyte formation 27 . In this experiment we observed severe osteophyte formation in two of the 6 BMP2 treated joints. Therefore, the results presented here, support the increased risk for intraarticular bone formation after BMP2 gene transfer into articular cartilage lesions. To further explore differences in IHH and BMP2 induced chondrogenesis, we have performed the immunolocalization of type X collagen as a marker of chondrocyte hypertrophy. We have only observed a marked type X collagen deposition in the BMP2 treated joints with severe intralesional bone formation, confirming previous in vitro experiments which described the increased expression of hypertrophy markers after BMP2 treatment of multipotent cells 6, 12, 28 . We recommend caution towards the application of BMP-2 or BMP2 gene transfer for cartilage repair due to the risk of osteophyte formation, particularly in conjunction with marrow stimulating techniques, which has been recommended previously 29 . One possible strategy to counter these risks, is the combination of BMP-2 with growth factors that mitigate hypertrophic differentiation 28 .
In contrast, the strategy proposed here aims to omit the induction of pathways that are activated by TGF-b superfamily members and to induce chondrogenic differentiation via pathways that don't trigger hypertrophic differentiation of chondrocytes and consecutive matrix mineralization. This is the first description of IHH's efficacy to improve histological repair cartilage quality in vivo. Hedgehog family members have important functions during development of various tissues, whereas IHH appears particularly promising for the stimulation of in vivo chondrogenesis due to it's regulatory function in the growth plate cartilage 14 .
Based on this experiment we conclude that IHH is capable to induce cartilage repair in vivo. However, future studies are needed to assess the underlying mechanisms of these findings in the context of in vivo cartilage repair. Additional biomechanical, biochemical and molecular genetic assays need to be utilized to comprehensively characterize the achieved neo-cartilage quality, and whether IHH can reduce the expression levels of hypertrophy markers in vivo, to the same degree as they were previously shown to be reduced in vitro 13 . Additionally, the effect of IHH protein on the expression of further target genes needs to be assessed, including anti-hypertrophic genes (i.e., PTHLH, encoding parathyroid hormone-related protein), anti-osteogenic genes (i.e., SOST, encoding for sclerostin) and markers of chondrocyte differentiation (i.e., genes encoding for type II collagen and proteoglycans).
